Credit: Image source: Getty Images.What happened
Shares of Insmed (NASDAQ: INSM) are down 16% at 12:22 EDT after the company gained Food and Drug Administration approval for its antibiotic Arikayce, which treats Mycobacterium avium complex lung disease. While certainly disappointing for shareholders, it's actually not all that uncommon for shares of a biotech to trade down after an FDA approval.
So what
Most of Insmed's decline today is likely just investors selling the news. The drug passed its phase 3 study -- causing shares to double overnight -- and an FDA advisory committee recommended 12-2 that the drug be approved, so a thumbs-up from the FDA was largely expected. Short-term investors are moving on to the next binary event.
Image source: Getty Images.
Investors might also be concerned about the boxed warning that Arikayce can cause lung problems that have "led to hospitalizations in some cases."
On the surface, that shouldn't be a problem, since the drug is approved for use in patients who have limited or no alternative treatment options. The bacterial infection is already causing lung issues of its own -- including potentially irreversible damage -- so it seems doctors would give Insmed's Arikayce a shot even with the potential side effects.
But investors are hoping the drug will also be used off label to treat newly diagnosed patients. Given the side-effect profile, doctors might be more interested in sticking with the current standard of care in those patients and using Arikayce as a last resort. Insurers might also be more likely to balk at paying for the drug as a first-line treatment if there's risk they could have to pay more to treat the side effects.
Now what
Today's knocked-down price could be a good buying opportunity, but investors will need to be patient, since drug launches are often slow to take off. Getting Arikayce approved is a great first step for Insmed, but convincing doctors to use the drug and insurers to pay for it will be just as difficult.
10 stocks we like better than Insmed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insmed wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
